The strong interim efficacy data positions FID-007 as a potential best-in-class therapy for R/M HNSCC. Traders should watch the ASCO 2026 presentation on June 1 for updated data, and monitor for partnership interest or regulatory path announcements. The data could drive significant upside for the stock in the near term.
Price Chart
Executive Summary
Fulgent Genetics announced interim Phase 2 data for FID-007 + cetuximab in R/M HNSCC, showing a 60% objective response rate and 7.2-month median progression-free survival, significantly exceeding historical benchmarks (5.8-19.1% ORR, 2.3-3.7 months PFS). The abstract was accepted for a Rapid Oral Session at ASCO 2026 (June 1). This is a meaningful clinical catalyst that de-risks the pipeline and supports further development.
Key Facts
- Objective response rate (ORR) of 60% in 42 evaluable patients (58% in Arm A, 61% in Arm B)
- Median progression-free survival (mPFS) of 7.2 months (6.7 months Arm A, 7.2 months Arm B)
- Median duration of response (DoR) 7.4 months with 56% of responders continuing to respond at data cutoff
- Historical standard of care ORR 5.8%-19.1% and mPFS 2.3-3.7 months
- Favorable safety profile with mostly Grade 1-2 TRAEs; one Grade 5 pneumonia in Arm B
- Abstract #6020 selected for Rapid Oral Session at ASCO 2026 on June 1, 2026
Financial Impact
No financial projections provided; positive clinical data could support future regulatory filing and partnership / licensing value for FID-007 in a large addressable market (~73,000 US HNSCC cases/year)
Risk Factors
- Interim Phase 2 data – results may not persist in larger Phase 3 trials
- One Grade 5 TRAE (pneumonia) raises safety vigilance
- Competition from approved PD-1 inhibitors and other novel therapies
- Company is a small cap with limited cash runway dependence on pipeline progress
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001674930-26-000025 |
| Document: flgt-ex99_1.htm | 0001674930-26-000025 |
| Document: 0001674930-26-000025-index-headers.html | 0001674930-26-000025 |
| Document: 0001674930-26-000025-index.html | 0001674930-26-000025 |
| Document: 0001674930-26-000025.txt | 0001674930-26-000025 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 28, 2026 21w ago | Insider Cluster | $18.14 $19.45 | ▲ +7.22% | ▲ +6.04% | $20.10 (+10.80%) |
May 28, 2026 21w ago | Insider Cluster | $18.14 $19.45 | ▲ +7.22% | ▲ +6.04% | $20.10 (+10.80%) |
May 21, 2026 22w ago | 8-K | $17.11 $18.57 | ▲ +8.53% | ▲ +5.34% | $20.10 (+17.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers